Advertisement
Mayo Clinic Proceedings Home

Neutropenic Colitis After Treatment of Acute Myelogenous Leukemia With Idarubicin and Cytosine Arabinoside

      Objective

      To determine the gastrointestinal toxic effects of idarubicin and cytosine arabinoside combination therapy in patients with newly diagnosed acute myelogenous leukemia (AML).

      Patients and Methods

      We performed a single-institution retrospective analysis of the incidence of neutropenic colitis in patients with newly diagnosed AML receiving idarubicin and cytosine arabinoside combination therapy. Using pharmacy records, we identified 78 patients who received idarubicin during the study period of January 1997 to September 1998 and who agreed to a review of their medical records. Patients with preexisting bowel conditions were excluded from this analysis. We used a strict definition of neutropenic colitis that included clinical findings (severe abdominal pain, diarrhea, hematochezia, and/or peritoneal signs) plus radiographic evidence of bowel inflammation in the absence of an identified bacterial pathogen.

      Results

      Of the 78 patients receiving idarubicin and cytosine arabinoside for treatment of AML, 65 were included in this study. We observed neutropenic colitis in 10 of these 65 AML patients. This complication was followed by sepsis in 3 patients and was the major cause of death in 4 of the 8 patients who died.

      Conclusion

      This analysis suggests that neutropenic colitis is a frequent and serious complication of idarubicin and cytosine arabinoside treatment.
      AML (acute myelogenous leukemia), CT (computed tomography)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Yates J
        • Glidewell O
        • Wiernik P
        • et al.
        Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.
        Blood. 1982; 60: 454-462
        • Wiernik PH
        • Banks PL
        • Case Jr, DC
        • et al.
        Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
        Blood. 1992; 79: 313-319
        • Vogler WR
        • Velez-Garcia E
        • Weiner RS
        • et al.
        A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
        J Clin Oncol. 1992; 10: 1103-1111
        • Mandelli F
        • Petti MC
        • Ardia A
        • et al.
        A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia: a multicentric study from the Italian Co-operative Group GIMEMA.
        Eur J Cancer. 1991; 27: 750-755
        • Berman E
        • Heller G
        • Santorsa J
        • et al.
        Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
        Blood. 1991; 77: 1666-1674
        • Rowe JM
        • Neuberg D
        • Friedenberg W
        • et al.
        A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993) [abstract].
        Blood. 1998; 92 (Abstract 1284.): 313a
        • AML Collaborative Group
        A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia.
        Br J Haematol. 1998; 103: 100-109
        • Gomez L
        • Martino R
        • Rolston KV
        Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases.
        Clin Infect Dis. 1998; 27: 695-699
        • Gorbach SL
        Neutropenic enterocolitis [editorial].
        Clin Infect Dis. 1998; 27: 700-701
        • Vlasveld LT
        • Zwaan FE
        • Fibbe WE
        • et al.
        Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: a potentiating role for amsacrine.
        Ann Hematol. 1991; 62: 129-134